Last reviewed · How we verify
Botulinum Toxin Type-A (day 0)
Botulinum toxin type-A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Botulinum toxin type-A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Facial wrinkles and expression lines (aesthetic use), Blepharospasm, Cervical dystonia.
At a glance
| Generic name | Botulinum Toxin Type-A (day 0) |
|---|---|
| Sponsor | Ivo Pitanguy Institute |
| Drug class | Neurotoxin; neuromuscular blocking agent |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Small molecule |
| Therapeutic area | Aesthetics; Neurology; Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
The toxin is a zinc-dependent endopeptidase that cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, resulting in flaccid paralysis of injected muscles. The effect is temporary, lasting 3–4 months, after which nerve terminals regenerate and muscle function returns.
Approved indications
- Facial wrinkles and expression lines (aesthetic use)
- Blepharospasm
- Cervical dystonia
- Chronic migraine
- Hyperhidrosis
Common side effects
- Headache
- Injection site pain or bruising
- Eyelid ptosis
- Facial weakness or asymmetry
- Flu-like symptoms
Key clinical trials
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults (PHASE3)
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults (PHASE3)
- Evaluation the Efficacy of Zinc on Botulinum Toxin A Injection (NA)
- Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections
- Double-blind Comparative Randomized Multicenter (PHASE3)
- Real World Effectiveness of Eptinezumab in Participants With Migraine (PHASE4)
- Assessing the Impact of Botulinum Toxin Type A on Facial Wrinkles: A Comprehensive Clinical Investigation
- Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botulinum Toxin Type-A (day 0) CI brief — competitive landscape report
- Botulinum Toxin Type-A (day 0) updates RSS · CI watch RSS
- Ivo Pitanguy Institute portfolio CI